When you, your child or loved one is diagnosed with Niemann-Pick disease it can have a profound effect on your whole family. For many people, a diagnosis of Niemann-Pick disease does not happen instantly and can come at the end of weeks or months of tests and investigations.
In many cases this can be the point from which you begin to contemplate the future…
During this period of adjustment you and your family may face what feels like a never-ending round of appointments as you begin to meet with the many professionals who will form a network of care around you or your loved one and you may find yourself having to tell your story time and time again. Hearing the news that your child or family member has a life-affecting disease, but that no one can tell you the exact path the disease will take, may make you feel that your hopes and dreams have been shattered.
At this time there is a lot to think about. Diagnosis comes at a point when you may not be capable of thinking clearly or taking information in.
We have people dedicated to support you to digest all the information:
If you would like to speak to someone about any aspect of the disease:
ALACHUA, FL – (Globe Newswire) – March 14, 2019 – CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that the company has initiated planning for a Phase I clinical trial for treatment of Alzheimer’s Disease. The trial will use Trappsol® Cyclo™, the company’s proprietary formulation of hydroxypropyl beta cyclodextrin, administered intravenously.Read more
IntraBio Clinical Trial Authorization Application Approved by the MHRA for the Treatment of Niemann-Pick Disease type C (NPC): OXFORD, UK, March 11, 2019-- IntraBio Inc., a late-stage biopharmaceutical company, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved its Clinical Trial Authorisation (CTA) Application for Clinical Trial IB1001-201 with its lead compound (IB1001) for the treatment of Niemann-Pick disease Type C (NPC).Read more